Abstract:A healthy immune system is pivotal for the hosts to resist external pathogens and maintain homeostasis; however, the immunosuppressive tumor microenvironment (TME) damages the anti-tumor immunity and promotes tumor progression, invasion, and metastasis. Recently, many studies have found that Foxp3+ regulatory T (Treg) cells are the major immunosuppressive cells that facilitate the formation of TME by promoting the development of various tumor-associated cells and suppressing the activity of effector immune cells. Considering the role of Tregs in tumor progression, it is pivotal to identify new therapeutic drugs to target and deplete Tregs in tumors. Although several studies have developed strategies for targeted deletion of Treg to reduce the TME and support the accumulation of effector T cells in tumors, Treg-targeted therapy systematically affects the Treg population and may lead to the progression of autoimmune diseases. It has been understood that, nevertheless, in disease conditions, Foxp3 undergoes several definite post-translational modifications (PTMs), including acetylation, glycosylation, phosphorylation, ubiquitylation, and methylation. These PTMs not only elevate or mitigate the transcriptional activity of Foxp3 but also affect the stability and immunosuppressive function of Tregs. Various studies have shown that pharmacological targeting of enzymes involved in PTMs can significantly influence the PTMs of Foxp3; thus, it may influence the progression of cancers and/or autoimmune diseases. Overall, this review will help researchers to understand the advances in the immune-suppressive mechanisms of Tregs, the post-translational regulations of Foxp3, and the potential therapeutic targets and strategies to target the Tregs in TME to improve anti-tumor immunity.

Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications

Foxp3 Post-translational Modifications and Treg Suppressive Activity

FoxP3 in Treg Cell Biology: a Molecular and Structural Perspective

Improving regulatory T cell-based therapy: insights into post-translational modification regulation

FoxP3 in T reg cell biology: a molecular and structural perspective

FoxP3 in T<sub>reg</sub> cell biology: a molecular and structural perspective

Transcriptional regulation of Foxp3 in regulatory T cells

Transcriptional Regulation of Foxp3 Gene: Multiple Signal Pathways on the Road

Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy

Molecular Mechanisms Controlling Foxp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation

FOXP3 and Its Cofactors As Targets of Immunotherapies

Molecular Mechanisms Underlying the Regulation and Functional Plasticity of FOXP3 + Regulatory T Cells

Regulatory T Cells: the Many Faces of Foxp3

The regulation of immune tolerance by FOXP3

Epigenetic Enzymes Are the Therapeutic Targets for CD4(+)CD25(+/high)Foxp3(+) Regulatory T Cells.

Control of Regulatory T Cells and T Helper Cells in Human Diseases: from Bench to Bedside.

Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations

Special Regulatory T-Cell Review: Foxp3 Biochemistry in Regulatory T Cells - How Diverse Signals Regulate Suppression

Foxp3, Regulatory T Cell, and Autoimmune Diseases

Histone Acetyltransferase Mediated Regulation of FOXP3 Acetylation and Treg Function.

T Cell Signaling Targets for Enhancing Regulatory or Effector Function.